N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer

Abstract

Background With a lack of specific symptoms, ovarian cancer (OV) is often diagnosed at an advanced stage. This coupled with inadequate prognostic indicators and treatments with limited therapeutic effect make OV the deadliest type of gynecological tumor. Recent research indicates that N6-methyladenosine (m6A) and long-chain non-coding RNA (lncRNA) play important roles in the prognosis of OV and the efficacy of immunotherapy. Results Using the Cancer Genome Atlas (TCGA) OV-related data set and the expression profiles of 21 m6A-related genes, we identified two m6A subtypes, and the differentially expressed genes between the two. Based on the differentially expressed lncRNAs in the two m6A subtypes and the lncRNAs co-expressed with the 21 m6A-related genes, single-factor cox and LASSO regression were used to further isolate the 13 major lncRNAs. Finally, multi-factor cox regression was used to construct a m6A-related lncRNA risk score model for OV, with good performance in patient prognosis. Using risk score, OV tumor samples are divided into with high- and low-score groups. We explored the differences in clinical characteristics, tumor mutational burden, and tumor immune cell infiltration between the two groups, and evaluated the risk score’s ability to predict the benefit of immunotherapy. Conclusion Our m6A-based lncRNA risk model could be used to predict the prognosis and immunotherapy response of future OV patients.

Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting

“…Using the OC-related dataset from The Cancer Genome Atlas (TCGA), Nie et al confirmed the prognostic potential of 21 m 6 A modifications in OC and identified two m 6 A subtypes using the m 6 A-related gene expression profiles [ 93 ]. Then, the authors established an OC risk model based on the differential expression pattern of lncRNAs between the m 6 A subtypes and lncRNAs co-expressed with the m 6 A-related genes [ 93 ]. The risk model not only simply evaluated the predictability of tumor prognosis using the risk score but also assessed the effectiveness of immunotherapy and developed novel and more accurate immunotherapies.…”

“…LncRNAs are a group of 200-nucleotides long RNA, which regulate gene expression and various physiological and pathological processes [91,92]. Using the OC-related dataset from The Cancer Genome Atlas (TCGA), Nie et al confirmed the prognostic potential of 21 m 6 A modifications in OC and identified two m 6 A subtypes using the m 6 A-related gene expression profiles [93]. Then, the authors established an OC risk model based on the differential expression pattern of lncRNAs between the m 6 A subtypes and lncRNAs co-expressed with the m 6 A-related genes [93].…”

Construction of Ovarian Cancer Prognostic Model Based on the Investigation of Ferroptosis-Related lncRNA

“…In addition, other potential markers, including circulating tumor DNA (ctDNA) [6], microRNAs (miRNAs) [7], and long non-coding RNAs (lncRNAs) [8], have been extensively studied in recent years and provide potential new methods for early diagnosis and prognosis. Research on lncRNA-based prognostic markers for OV has led to the development of prognostic models, including immune [9], autophagy [10], and N6methyladenosine-related lncRNA prognostic models [11]. We are currently investigating a new method to improve prognosis of patients with OV.…”